LV13074B - Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors - Google Patents
Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors Download PDFInfo
- Publication number
- LV13074B LV13074B LVP-03-48A LV030048A LV13074B LV 13074 B LV13074 B LV 13074B LV 030048 A LV030048 A LV 030048A LV 13074 B LV13074 B LV 13074B
- Authority
- LV
- Latvia
- Prior art keywords
- halogen
- alkoxy
- alkyl
- hydrogen
- compounds
- Prior art date
Links
- 229940054066 benzamide antipsychotics Drugs 0.000 title abstract 2
- 150000003936 benzamides Chemical class 0.000 title abstract 2
- 239000002571 phosphodiesterase inhibitor Substances 0.000 title description 6
- 101000909851 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) cAMP/cGMP dual specificity phosphodiesterase Rv0805 Proteins 0.000 title 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 6
- 208000017520 skin disease Diseases 0.000 claims abstract description 5
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 201000008482 osteoarthritis Diseases 0.000 claims abstract description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 4
- 206010019280 Heart failures Diseases 0.000 claims abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 6
- 208000004998 Abdominal Pain Diseases 0.000 claims abstract 2
- 208000000884 Airway Obstruction Diseases 0.000 claims abstract 2
- 208000002881 Colic Diseases 0.000 claims abstract 2
- 206010061218 Inflammation Diseases 0.000 claims abstract 2
- 208000000913 Kidney Calculi Diseases 0.000 claims abstract 2
- 206010029148 Nephrolithiasis Diseases 0.000 claims abstract 2
- 230000001154 acute effect Effects 0.000 claims abstract 2
- 230000004054 inflammatory process Effects 0.000 claims abstract 2
- 210000003734 kidney Anatomy 0.000 claims abstract 2
- 230000035939 shock Effects 0.000 claims abstract 2
- -1 cyano, carboxyl Chemical group 0.000 claims description 221
- 229910052736 halogen Inorganic materials 0.000 claims description 81
- 150000002367 halogens Chemical class 0.000 claims description 78
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 52
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 40
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 28
- 125000004076 pyridyl group Chemical group 0.000 claims description 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 23
- 150000001204 N-oxides Chemical class 0.000 claims description 21
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 20
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 20
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 17
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 17
- 229910052731 fluorine Inorganic materials 0.000 claims description 16
- 239000011737 fluorine Substances 0.000 claims description 15
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 13
- 125000001153 fluoro group Chemical group F* 0.000 claims description 10
- KLIDCXVFHGNTTM-UHFFFAOYSA-N 2,6-dimethoxyphenol Chemical group COC1=CC=CC(OC)=C1O KLIDCXVFHGNTTM-UHFFFAOYSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- APJAEXGNDLFGPD-AWCRTANDSA-N 3-amino-n-{4-[2-(2,6-dimethyl-phenoxy)-acetylamino]-3-hydroxy-1-isobutyl-5-phenyl-pentyl}-benzamide Chemical compound C([C@@H]([C@@H](O)C[C@H](CC(C)C)NC(=O)C=1C=CC(N)=CC=1)NC(=O)COC=1C(=CC=CC=1C)C)C1=CC=CC=C1 APJAEXGNDLFGPD-AWCRTANDSA-N 0.000 claims description 6
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- WQUBEIMCFHCJCO-AWCRTANDSA-N 4-amino-n-{4-[2-(2,6-dimethyl-phenoxy)-acetylamino]-3-hydroxy-1-isobutyl-5-phenyl-pentyl}-benzamide Chemical compound C([C@@H]([C@@H](O)C[C@H](CC(C)C)NC(=O)C=1C=C(N)C=CC=1)NC(=O)COC=1C(=CC=CC=1C)C)C1=CC=CC=C1 WQUBEIMCFHCJCO-AWCRTANDSA-N 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 25
- 239000001257 hydrogen Substances 0.000 claims 25
- 150000001875 compounds Chemical class 0.000 claims 23
- 150000002431 hydrogen Chemical class 0.000 claims 13
- SCEVBRBKKQZTKM-UHFFFAOYSA-N 5-[[6-chloro-5-(1-methylindol-5-yl)-1H-benzimidazol-2-yl]oxy]-N-hydroxy-2-methylbenzamide Chemical compound ClC=1C(=CC2=C(NC(=N2)OC=2C=CC(=C(C(=O)NO)C=2)C)C=1)C=1C=C2C=CN(C2=CC=1)C SCEVBRBKKQZTKM-UHFFFAOYSA-N 0.000 claims 4
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical class [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 claims 4
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 claims 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000030090 Acute Disease Diseases 0.000 claims 1
- 208000014085 Chronic respiratory disease Diseases 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 150000003222 pyridines Chemical class 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 abstract 4
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 210000000626 ureter Anatomy 0.000 abstract 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 9
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- HNBFKIZYKBBZMG-UHFFFAOYSA-N 4-(difluoromethoxy)-3-(2,2,2-trifluoroethoxy)benzaldehyde Chemical compound FC(F)OC1=CC=C(C=O)C=C1OCC(F)(F)F HNBFKIZYKBBZMG-UHFFFAOYSA-N 0.000 description 7
- 208000006673 asthma Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 5
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 102000003390 tumor necrosis factor Human genes 0.000 description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- KGPOVKAYCXTCQS-UHFFFAOYSA-N 4-(difluoromethoxy)-3-methoxybenzaldehyde Chemical compound COC1=CC(C=O)=CC=C1OC(F)F KGPOVKAYCXTCQS-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 206010039083 rhinitis Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- UFFBMTHBGFGIHF-UHFFFAOYSA-N 2,6-dimethylaniline Chemical compound CC1=CC=CC(C)=C1N UFFBMTHBGFGIHF-UHFFFAOYSA-N 0.000 description 2
- CCJAYIGMMRQRAO-UHFFFAOYSA-N 2-[4-[(2-hydroxyphenyl)methylideneamino]butyliminomethyl]phenol Chemical compound OC1=CC=CC=C1C=NCCCCN=CC1=CC=CC=C1O CCJAYIGMMRQRAO-UHFFFAOYSA-N 0.000 description 2
- AHVVCELVGCPYGI-UHFFFAOYSA-N 3-(cyclopropylmethoxy)-4-(difluoromethoxy)benzaldehyde Chemical compound FC(F)OC1=CC=C(C=O)C=C1OCC1CC1 AHVVCELVGCPYGI-UHFFFAOYSA-N 0.000 description 2
- QEZBOPWZULAPBJ-UHFFFAOYSA-N 4-(difluoromethoxy)-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1OC(F)F QEZBOPWZULAPBJ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 108010008211 N-Formylmethionine Leucyl-Phenylalanine Proteins 0.000 description 2
- PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- RNVCVTLRINQCPJ-UHFFFAOYSA-N o-toluidine Chemical compound CC1=CC=CC=C1N RNVCVTLRINQCPJ-UHFFFAOYSA-N 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000019254 respiratory burst Effects 0.000 description 2
- 231100000489 sensitizer Toxicity 0.000 description 2
- 206010040560 shock Diseases 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 2
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 2
- 235000012141 vanillin Nutrition 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- HJMQDJPMQIHLPB-UHFFFAOYSA-N zardaverine Chemical compound C1=C(OC(F)F)C(OC)=CC(C2=NNC(=O)C=C2)=C1 HJMQDJPMQIHLPB-UHFFFAOYSA-N 0.000 description 2
- 229950001080 zardaverine Drugs 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- PLVFNMQHMRRBAA-UHFFFAOYSA-N 2,3,5,6-tetrafluoropyridin-4-amine Chemical compound NC1=C(F)C(F)=NC(F)=C1F PLVFNMQHMRRBAA-UHFFFAOYSA-N 0.000 description 1
- 125000001617 2,3-dimethoxy phenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 1
- ODUZJBKKYBQIBX-UHFFFAOYSA-N 2,6-difluoroaniline Chemical compound NC1=C(F)C=CC=C1F ODUZJBKKYBQIBX-UHFFFAOYSA-N 0.000 description 1
- YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
- WFNLHDJJZSJARK-UHFFFAOYSA-N 2-chloro-6-methylaniline Chemical compound CC1=CC=CC(Cl)=C1N WFNLHDJJZSJARK-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- MEQBJJUWDCYIAB-UHFFFAOYSA-N 2-chloropyridin-3-amine Chemical compound NC1=CC=CN=C1Cl MEQBJJUWDCYIAB-UHFFFAOYSA-N 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- BZSXEZOLBIJVQK-UHFFFAOYSA-N 2-methylsulfonylbenzoic acid Chemical compound CS(=O)(=O)C1=CC=CC=C1C(O)=O BZSXEZOLBIJVQK-UHFFFAOYSA-N 0.000 description 1
- IPHURZAZBKLMQJ-UHFFFAOYSA-N 3,4-bis(difluoromethoxy)benzaldehyde Chemical compound FC(F)OC1=CC=C(C=O)C=C1OC(F)F IPHURZAZBKLMQJ-UHFFFAOYSA-N 0.000 description 1
- UPVZJUHNXCOOHH-UHFFFAOYSA-N 3,4-bis(difluoromethoxy)benzoic acid Chemical compound OC(=O)C1=CC=C(OC(F)F)C(OC(F)F)=C1 UPVZJUHNXCOOHH-UHFFFAOYSA-N 0.000 description 1
- BEGINUFBBRTGBH-UHFFFAOYSA-N 3,5-dichloro-2,6-difluoropyridin-4-amine Chemical compound NC1=C(Cl)C(F)=NC(F)=C1Cl BEGINUFBBRTGBH-UHFFFAOYSA-N 0.000 description 1
- PBMSPXWTKREEHG-UHFFFAOYSA-N 3,5-dichloro-3h-pyridin-4-one Chemical compound ClC1C=NC=C(Cl)C1=O PBMSPXWTKREEHG-UHFFFAOYSA-N 0.000 description 1
- ISIQAMHROGZHOV-UHFFFAOYSA-N 3,5-dichloropyridin-4-amine Chemical compound NC1=C(Cl)C=NC=C1Cl ISIQAMHROGZHOV-UHFFFAOYSA-N 0.000 description 1
- XQNXIUNBRPORON-UHFFFAOYSA-N 3-(cyclobutylmethoxy)-4-(difluoromethoxy)benzaldehyde Chemical compound FC(F)OC1=CC=C(C=O)C=C1OCC1CCC1 XQNXIUNBRPORON-UHFFFAOYSA-N 0.000 description 1
- ZCNMBDBEKFFBGL-UHFFFAOYSA-N 3-(cyclobutylmethoxy)-4-(difluoromethoxy)benzoic acid Chemical compound OC(=O)C1=CC=C(OC(F)F)C(OCC2CCC2)=C1 ZCNMBDBEKFFBGL-UHFFFAOYSA-N 0.000 description 1
- HRSLBKVJXAUVBM-UHFFFAOYSA-N 3-(cyclobutylmethoxy)-n-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CCC1 HRSLBKVJXAUVBM-UHFFFAOYSA-N 0.000 description 1
- IGFDIFLMMLWKKY-UHFFFAOYSA-N 3-(cyclopropylmethoxy)-4-(difluoromethoxy)benzoic acid Chemical compound OC(=O)C1=CC=C(OC(F)F)C(OCC2CC2)=C1 IGFDIFLMMLWKKY-UHFFFAOYSA-N 0.000 description 1
- ZIOBKYXYQVFUJT-UHFFFAOYSA-N 3-(difluoromethoxy)-4-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1OC(F)F ZIOBKYXYQVFUJT-UHFFFAOYSA-N 0.000 description 1
- DDERGTQRHJFPCR-UHFFFAOYSA-N 3-(difluoromethoxy)-4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1OC(F)F DDERGTQRHJFPCR-UHFFFAOYSA-N 0.000 description 1
- GLFNFWWXXOQGCI-UHFFFAOYSA-N 3-(difluoromethoxy)-4-phenylmethoxybenzoic acid Chemical compound FC(F)OC1=CC(C(=O)O)=CC=C1OCC1=CC=CC=C1 GLFNFWWXXOQGCI-UHFFFAOYSA-N 0.000 description 1
- PCIGFJWHCSCDSB-UHFFFAOYSA-N 3-(difluoromethoxy)-4-propoxybenzaldehyde Chemical compound CCCOC1=CC=C(C=O)C=C1OC(F)F PCIGFJWHCSCDSB-UHFFFAOYSA-N 0.000 description 1
- LHKYLJLPRAYLOL-UHFFFAOYSA-N 3-(difluoromethoxy)-4-propoxybenzoic acid Chemical compound CCCOC1=CC=C(C(O)=O)C=C1OC(F)F LHKYLJLPRAYLOL-UHFFFAOYSA-N 0.000 description 1
- HMQHRMSMILARRD-UHFFFAOYSA-N 3-(difluoromethoxy)-n-(2,6-dimethylphenyl)-4-methoxybenzamide Chemical compound C1=C(OC(F)F)C(OC)=CC=C1C(=O)NC1=C(C)C=CC=C1C HMQHRMSMILARRD-UHFFFAOYSA-N 0.000 description 1
- IJGMBUFHHBUVNG-UHFFFAOYSA-N 3-chloro-2,5,6-trifluoropyridin-4-amine Chemical compound NC1=C(F)C(F)=NC(F)=C1Cl IJGMBUFHHBUVNG-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- FQHDWLJLONFERM-UHFFFAOYSA-N 3-cyclopentyloxy-4-(difluoromethoxy)benzaldehyde Chemical compound FC(F)OC1=CC=C(C=O)C=C1OC1CCCC1 FQHDWLJLONFERM-UHFFFAOYSA-N 0.000 description 1
- CXORGSNJRFZYCQ-UHFFFAOYSA-N 3-cyclopentyloxy-n-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OC1CCCC1 CXORGSNJRFZYCQ-UHFFFAOYSA-N 0.000 description 1
- MVKDNXIKAWKCCS-UHFFFAOYSA-N 3-methyl-1h-pyridin-2-one Chemical compound CC1=CC=CN=C1O MVKDNXIKAWKCCS-UHFFFAOYSA-N 0.000 description 1
- RGDQRXPEZUNWHX-UHFFFAOYSA-N 3-methylpyridin-2-amine Chemical class CC1=CC=CN=C1N RGDQRXPEZUNWHX-UHFFFAOYSA-N 0.000 description 1
- GMUQKCKJXAMWGY-UHFFFAOYSA-N 4-(cyclopropylmethoxy)-3-(difluoromethoxy)benzaldehyde Chemical compound FC(F)OC1=CC(C=O)=CC=C1OCC1CC1 GMUQKCKJXAMWGY-UHFFFAOYSA-N 0.000 description 1
- SEOHJHSFPYMOGS-UHFFFAOYSA-N 4-(cyclopropylmethoxy)-3-(difluoromethoxy)benzoic acid Chemical compound FC(F)OC1=CC(C(=O)O)=CC=C1OCC1CC1 SEOHJHSFPYMOGS-UHFFFAOYSA-N 0.000 description 1
- VXNCCFGMEHFNBA-UHFFFAOYSA-N 4-(cyclopropylmethoxy)-n-(3,5-dichloropyridin-4-yl)-3-(difluoromethoxy)benzamide Chemical compound FC(F)OC1=CC(C(=O)NC=2C(=CN=CC=2Cl)Cl)=CC=C1OCC1CC1 VXNCCFGMEHFNBA-UHFFFAOYSA-N 0.000 description 1
- OXZADOZACZPTHF-UHFFFAOYSA-N 4-(difluoromethoxy)-3-(2,2,2-trifluoroethoxy)benzoic acid Chemical compound OC(=O)C1=CC=C(OC(F)F)C(OCC(F)(F)F)=C1 OXZADOZACZPTHF-UHFFFAOYSA-N 0.000 description 1
- QNWHIZZAHNHCNA-UHFFFAOYSA-N 4-(difluoromethoxy)-3-(2-methylpropoxy)benzaldehyde Chemical compound CC(C)COC1=CC(C=O)=CC=C1OC(F)F QNWHIZZAHNHCNA-UHFFFAOYSA-N 0.000 description 1
- GYRYHZYEFPCQIZ-UHFFFAOYSA-N 4-(difluoromethoxy)-3-ethoxybenzaldehyde Chemical compound CCOC1=CC(C=O)=CC=C1OC(F)F GYRYHZYEFPCQIZ-UHFFFAOYSA-N 0.000 description 1
- FPNSIXUGULJPGQ-UHFFFAOYSA-N 4-(difluoromethoxy)-3-ethoxybenzoic acid Chemical compound CCOC1=CC(C(O)=O)=CC=C1OC(F)F FPNSIXUGULJPGQ-UHFFFAOYSA-N 0.000 description 1
- QXZUETIKDFOLIZ-UHFFFAOYSA-N 4-(difluoromethoxy)-3-methoxy-n-(2,3,5,6-tetrafluoropyridin-4-yl)benzamide Chemical compound C1=C(OC(F)F)C(OC)=CC(C(=O)NC=2C(=C(F)N=C(F)C=2F)F)=C1 QXZUETIKDFOLIZ-UHFFFAOYSA-N 0.000 description 1
- QQOBZRIUBPHXQZ-UHFFFAOYSA-N 4-(difluoromethoxy)-3-methoxy-n-(2,4,6-trifluorophenyl)benzamide Chemical compound C1=C(OC(F)F)C(OC)=CC(C(=O)NC=2C(=CC(F)=CC=2F)F)=C1 QQOBZRIUBPHXQZ-UHFFFAOYSA-N 0.000 description 1
- KCPYWNGKUVYDTM-UHFFFAOYSA-N 4-(difluoromethoxy)-3-methoxy-n-(2-methylphenyl)benzamide Chemical compound C1=C(OC(F)F)C(OC)=CC(C(=O)NC=2C(=CC=CC=2)C)=C1 KCPYWNGKUVYDTM-UHFFFAOYSA-N 0.000 description 1
- HNVVHTWTKJJYHC-UHFFFAOYSA-N 4-(difluoromethoxy)-3-methoxy-n-(3-methylpyridin-2-yl)benzamide Chemical compound C1=C(OC(F)F)C(OC)=CC(C(=O)NC=2C(=CC=CN=2)C)=C1 HNVVHTWTKJJYHC-UHFFFAOYSA-N 0.000 description 1
- WNFICMVDQROOEO-UHFFFAOYSA-N 4-(difluoromethoxy)-n-(2,6-difluorophenyl)-3-methoxybenzamide Chemical compound C1=C(OC(F)F)C(OC)=CC(C(=O)NC=2C(=CC=CC=2F)F)=C1 WNFICMVDQROOEO-UHFFFAOYSA-N 0.000 description 1
- MMSLLYVDMJHLFS-UHFFFAOYSA-N 4-(difluoromethoxy)-n-(2,6-dimethylphenyl)-3-methoxybenzamide Chemical compound C1=C(OC(F)F)C(OC)=CC(C(=O)NC=2C(=CC=CC=2C)C)=C1 MMSLLYVDMJHLFS-UHFFFAOYSA-N 0.000 description 1
- HOFVLYKJGRRPSJ-UHFFFAOYSA-N 4-butoxy-3-(difluoromethoxy)benzaldehyde Chemical compound CCCCOC1=CC=C(C=O)C=C1OC(F)F HOFVLYKJGRRPSJ-UHFFFAOYSA-N 0.000 description 1
- IPUDZYJAANZVMW-UHFFFAOYSA-N 4-butoxy-3-(difluoromethoxy)benzoic acid Chemical compound CCCCOC1=CC=C(C(O)=O)C=C1OC(F)F IPUDZYJAANZVMW-UHFFFAOYSA-N 0.000 description 1
- JNILPKSNJYEQLP-UHFFFAOYSA-N 4-butoxy-n-(3,5-dichloropyridin-4-yl)-3-(difluoromethoxy)benzamide Chemical compound C1=C(OC(F)F)C(OCCCC)=CC=C1C(=O)NC1=C(Cl)C=NC=C1Cl JNILPKSNJYEQLP-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010052613 Allergic bronchitis Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 description 1
- 241000511343 Chondrostoma nasus Species 0.000 description 1
- 206010009137 Chronic sinusitis Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 241001050985 Disco Species 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 241001295925 Gegenes Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000000592 Nasal Polyps Diseases 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- LNHDBFYOJMPJEI-UHFFFAOYSA-N OC(C(C=CC(OC(F)F)=C1)=C1OC1CCCC1)=O Chemical compound OC(C(C=CC(OC(F)F)=C1)=C1OC1CCCC1)=O LNHDBFYOJMPJEI-UHFFFAOYSA-N 0.000 description 1
- 241000272108 Ophiophagus hannah Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- KXHPPCXNWTUNSB-UHFFFAOYSA-M benzyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC1=CC=CC=C1 KXHPPCXNWTUNSB-UHFFFAOYSA-M 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 125000003113 cycloheptyloxy group Chemical group C1(CCCCCC1)O* 0.000 description 1
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- HEVOBTQDAJFQRW-UHFFFAOYSA-N ethyl 3,5-dichloro-4-[[4-(difluoromethoxy)-3-methoxybenzoyl]amino]benzoate Chemical compound ClC1=CC(C(=O)OCC)=CC(Cl)=C1NC(=O)C1=CC=C(OC(F)F)C(OC)=C1 HEVOBTQDAJFQRW-UHFFFAOYSA-N 0.000 description 1
- MIDALAPASRDTOZ-UHFFFAOYSA-N ethyl 4-amino-3,5-dichlorobenzoate Chemical compound CCOC(=O)C1=CC(Cl)=C(N)C(Cl)=C1 MIDALAPASRDTOZ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- JCVDBOUTLJHCBS-UHFFFAOYSA-N n-(2,6-dichlorophenyl)-3-(difluoromethoxy)-4-methoxybenzamide Chemical compound C1=C(OC(F)F)C(OC)=CC=C1C(=O)NC1=C(Cl)C=CC=C1Cl JCVDBOUTLJHCBS-UHFFFAOYSA-N 0.000 description 1
- LFGYAFCPYRIXPX-UHFFFAOYSA-N n-(2,6-dichlorophenyl)-4-(difluoromethoxy)-3-methoxybenzamide Chemical compound C1=C(OC(F)F)C(OC)=CC(C(=O)NC=2C(=CC=CC=2Cl)Cl)=C1 LFGYAFCPYRIXPX-UHFFFAOYSA-N 0.000 description 1
- ZTVCCFIMOSCDDH-UHFFFAOYSA-N n-(2-bromophenyl)-4-(difluoromethoxy)-3-methoxybenzamide Chemical compound C1=C(OC(F)F)C(OC)=CC(C(=O)NC=2C(=CC=CC=2)Br)=C1 ZTVCCFIMOSCDDH-UHFFFAOYSA-N 0.000 description 1
- GHUZCHMSHCMSJI-UHFFFAOYSA-N n-(2-chloro-6-methylphenyl)-4-(difluoromethoxy)-3-methoxybenzamide Chemical compound C1=C(OC(F)F)C(OC)=CC(C(=O)NC=2C(=CC=CC=2C)Cl)=C1 GHUZCHMSHCMSJI-UHFFFAOYSA-N 0.000 description 1
- SBOJWSQBAATCGB-UHFFFAOYSA-N n-(3,5-dibromopyridin-2-yl)-3-(difluoromethoxy)-4-methoxybenzamide Chemical compound C1=C(OC(F)F)C(OC)=CC=C1C(=O)NC1=NC=C(Br)C=C1Br SBOJWSQBAATCGB-UHFFFAOYSA-N 0.000 description 1
- YKOXXQRGTUQZBD-UHFFFAOYSA-N n-(3,5-dibromopyridin-2-yl)-4-(difluoromethoxy)-3-methoxybenzamide Chemical compound C1=C(OC(F)F)C(OC)=CC(C(=O)NC=2C(=CC(Br)=CN=2)Br)=C1 YKOXXQRGTUQZBD-UHFFFAOYSA-N 0.000 description 1
- RRPIVAZLZODPMJ-UHFFFAOYSA-N n-(3,5-dichloro-2,6-difluoropyridin-4-yl)-3-(difluoromethoxy)-4-methoxybenzamide Chemical compound C1=C(OC(F)F)C(OC)=CC=C1C(=O)NC1=C(Cl)C(F)=NC(F)=C1Cl RRPIVAZLZODPMJ-UHFFFAOYSA-N 0.000 description 1
- XEEYQZLITBSFSS-UHFFFAOYSA-N n-(3,5-dichloro-2,6-difluoropyridin-4-yl)-4-(difluoromethoxy)-3-methoxybenzamide Chemical compound C1=C(OC(F)F)C(OC)=CC(C(=O)NC=2C(=C(F)N=C(F)C=2Cl)Cl)=C1 XEEYQZLITBSFSS-UHFFFAOYSA-N 0.000 description 1
- OIYBMFARPXRQBW-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-3,4-bis(difluoromethoxy)benzamide Chemical compound C1=C(OC(F)F)C(OC(F)F)=CC=C1C(=O)NC1=C(Cl)C=NC=C1Cl OIYBMFARPXRQBW-UHFFFAOYSA-N 0.000 description 1
- BXGJICHTBHPIBQ-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-3-(difluoromethoxy)-4-methoxybenzamide Chemical compound C1=C(OC(F)F)C(OC)=CC=C1C(=O)NC1=C(Cl)C=NC=C1Cl BXGJICHTBHPIBQ-UHFFFAOYSA-N 0.000 description 1
- MUIRPHYNWQPHOL-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-3-(difluoromethoxy)-4-propoxybenzamide Chemical compound C1=C(OC(F)F)C(OCCC)=CC=C1C(=O)NC1=C(Cl)C=NC=C1Cl MUIRPHYNWQPHOL-UHFFFAOYSA-N 0.000 description 1
- OCNFWKOLNRGAML-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-ethoxybenzamide Chemical compound C1=C(OC(F)F)C(OCC)=CC(C(=O)NC=2C(=CN=CC=2Cl)Cl)=C1 OCNFWKOLNRGAML-UHFFFAOYSA-N 0.000 description 1
- SPLANDZBYAJGBL-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-methoxybenzamide Chemical compound C1=C(OC(F)F)C(OC)=CC(C(=O)NC=2C(=CN=CC=2Cl)Cl)=C1 SPLANDZBYAJGBL-UHFFFAOYSA-N 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 1
- 229960002218 sodium chlorite Drugs 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH199693 | 1993-07-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LV13074B true LV13074B (en) | 2004-03-20 |
Family
ID=4223466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LVP-03-48A LV13074B (en) | 1993-07-02 | 2003-05-13 | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US5712298A (OSRAM) |
| EP (1) | EP0706513B1 (OSRAM) |
| JP (1) | JP3093271B2 (OSRAM) |
| KR (1) | KR100331255B1 (OSRAM) |
| CN (1) | CN1046939C (OSRAM) |
| AT (1) | ATE217612T1 (OSRAM) |
| AU (1) | AU687087B2 (OSRAM) |
| CA (1) | CA2165192C (OSRAM) |
| CY (2) | CY2389B1 (OSRAM) |
| CZ (1) | CZ290266B6 (OSRAM) |
| DE (2) | DE122010000043I1 (OSRAM) |
| DK (1) | DK0706513T3 (OSRAM) |
| ES (1) | ES2176252T3 (OSRAM) |
| FI (1) | FI112864B (OSRAM) |
| FR (1) | FR10C0052I2 (OSRAM) |
| HU (1) | HU220041B (OSRAM) |
| LU (1) | LU91709I2 (OSRAM) |
| LV (1) | LV13074B (OSRAM) |
| NO (2) | NO305598B1 (OSRAM) |
| NZ (1) | NZ271316A (OSRAM) |
| PL (1) | PL178314B1 (OSRAM) |
| PT (1) | PT706513E (OSRAM) |
| RU (1) | RU2137754C1 (OSRAM) |
| SG (1) | SG143011A1 (OSRAM) |
| SI (1) | SI0706513T1 (OSRAM) |
| SK (1) | SK283263B6 (OSRAM) |
| WO (1) | WO1995001338A1 (OSRAM) |
Families Citing this family (203)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698711A (en) * | 1991-01-28 | 1997-12-16 | Rhone-Poulenc Rorer Limited | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group |
| GB9311281D0 (en) * | 1993-06-01 | 1993-07-21 | Rhone Poulenc Rorer Ltd | Novel composition of matter |
| US6096768A (en) * | 1992-01-28 | 2000-08-01 | Rhone-Poulenc Rorer Limited | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group |
| AU6526896A (en) * | 1995-07-22 | 1997-02-18 | Rhone-Poulenc Rorer Limited | Substituted aromatic compounds and their pharmaceutical use |
| ES2188983T4 (es) * | 1996-08-19 | 2004-06-01 | Altana Pharma Ag | Nuevas benzofuran-4-carboxamidas. |
| US5874437A (en) * | 1996-11-01 | 1999-02-23 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
| US6331543B1 (en) | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
| USRE37234E1 (en) * | 1996-11-01 | 2001-06-19 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses |
| US5958926A (en) | 1996-11-01 | 1999-09-28 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
| EP0941086A4 (en) * | 1996-11-01 | 2000-07-12 | Nitromed Inc | NITROSIZED AND NITROSYLATED PHOSPHODIESTERASE INHIBITING COMPOUNDS, COMPOSITIONS AND THEIR USE |
| DE69835594T2 (de) * | 1997-02-17 | 2007-08-16 | Altana Pharma Ag | Zusammensetzungen zur behandlung von irds oder ards die 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy) benzamid und lungensurfactant enthalten |
| US6472425B1 (en) | 1997-10-31 | 2002-10-29 | Nitromed, Inc. | Methods for treating female sexual dysfunctions |
| US6118017A (en) * | 1998-04-14 | 2000-09-12 | Smithkline Beecham Corporation | Substituted-(3-cyclopentyloxy-4-methoxyphenyl)-3-phenylcyanocyclobutan-1-one |
| CA2364258C (en) * | 1999-03-10 | 2008-12-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh | 3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid-4-yl)benzamide in the treatment of multiple sclerosis |
| US6653309B1 (en) * | 1999-04-26 | 2003-11-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme technical field of the invention |
| EP1176960B1 (en) * | 1999-05-04 | 2004-09-29 | ALTANA Pharma AG | Synergistic combination comprising roflumilast and a pde-3 inhibitor |
| ATE320800T1 (de) | 1999-08-21 | 2006-04-15 | Altana Pharma Ag | Synergistische kombination von roflumilast und salmeterol |
| WO2001090076A1 (en) * | 2000-05-25 | 2001-11-29 | Merck Frosst Canada & Co. | Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor |
| DE10043074A1 (de) * | 2000-09-01 | 2002-03-14 | Aventis Cropscience Gmbh | Herbizid wirksame Benzoylcyclohexandione |
| EP1199074A1 (en) * | 2000-09-15 | 2002-04-24 | Warner-Lambert Company | Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
| EP1188438A1 (en) * | 2000-09-15 | 2002-03-20 | Warner-Lambert Company | Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production |
| AU2002227123A1 (en) * | 2000-11-07 | 2002-05-21 | Merck And Co., Inc. | Method of treatment with a combination of a pde4 inhibitor and a leukotriene antagonist |
| US20100310477A1 (en) * | 2000-11-28 | 2010-12-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg. | Pharmaceutical compositions based on anticholingerics and additional active ingredients |
| US6699890B2 (en) | 2000-12-22 | 2004-03-02 | Memory Pharmaceuticals Corp. | Phosphodiesterase 4 inhibitors |
| US7153871B2 (en) | 2001-01-22 | 2006-12-26 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs |
| US7205320B2 (en) * | 2001-01-22 | 2007-04-17 | Memory Pharmaceuticals Corp. | Phosphodiesterase 4 inhibitors |
| US6872382B1 (en) | 2001-05-21 | 2005-03-29 | Alcon, Inc. | Use of selective PDE IV inhibitors to treat dry eye disorders |
| WO2002094823A1 (en) | 2001-05-24 | 2002-11-28 | Merck Frosst Canada & Co. | 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors |
| PL368129A1 (en) * | 2001-08-09 | 2005-03-21 | Ono Pharmaceutical Co, Ltd. | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient |
| MY140561A (en) * | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
| DE10207160A1 (de) * | 2002-02-20 | 2003-12-18 | Altana Pharma Ag | Darreichungsform enthaltend PDE 4-Hemmer als Wirkstoff |
| TWI347845B (en) * | 2002-03-06 | 2011-09-01 | Nycomed Gmbh | Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same |
| RU2227797C2 (ru) * | 2002-03-29 | 2004-04-27 | Пермская государственная фармацевтическая академия | 4-метил-2-пиридиламид тетрахлорфталевой кислоты, проявляющий гипертензивную активность |
| JP2005528418A (ja) * | 2002-05-07 | 2005-09-22 | アルタナ ファルマ アクチエンゲゼルシャフト | 気道疾患を治療するための新規組み合わせ |
| MXPA04011019A (es) * | 2002-05-07 | 2005-01-25 | Altana Pharma Ag | Combinacion de un inhibidor de la bomba de protones y un agente respiratorio, para el tratamiento de trastornos de las vias respiratorias. |
| EP1505972A2 (en) * | 2002-05-16 | 2005-02-16 | Pharmacia Corporation | A selective inos inhibitor and a pde inhibitor in combination for the treatment of respiratory diseases |
| EA010416B1 (ru) * | 2002-05-28 | 2008-08-29 | Никомед Гмбх | Фармацевтический препарат для местного применения на основе рофлумиласта и полиэтиленгликоля |
| CN100381425C (zh) * | 2002-07-19 | 2008-04-16 | 记忆药物公司 | 作为磷酸二酯酶4抑制剂的6-氨基-1h-吲唑及其药物组合物和用途 |
| RU2368604C2 (ru) | 2002-07-19 | 2009-09-27 | Мемори Фармасьютиклз Корпорейшн | Ингибиторы фосфодиэстеразы 4, включающие n-замещенные аналоги анилина и дифениламина |
| WO2004022536A1 (en) * | 2002-09-04 | 2004-03-18 | Glenmark Pharmaceuticals Limited | New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
| AU2003288901A1 (en) * | 2002-09-06 | 2004-03-29 | Merck And Co., Inc. | Treatment of rheumatoid arthritis by inhibition of pde4 |
| PL374700A1 (pl) * | 2002-09-20 | 2005-10-31 | Alcon, Inc. | Zastosowanie inhibitorów syntezy cytokiny do leczenia zespołu suchego oka |
| US6822114B1 (en) | 2002-10-08 | 2004-11-23 | Albemarle Corporation | Process for production of fluoroalkoxy-substituted benzamides and their intermediates |
| KR20050065624A (ko) | 2002-10-23 | 2005-06-29 | 그렌마크 파머수티칼스 엘티디. | 염증성 및 알레르기 질환의 치료에 유용한 신규한트리사이클릭 화합물, 이의 제조 방법 및 이를 함유하는약제 조성물 |
| AU2003295656B2 (en) * | 2002-11-19 | 2010-11-11 | Memory Pharmaceuticals Corporation | Pyridine N-oxide compounds as phosphodiesterase 4 inhibitors |
| DE60321953D1 (de) * | 2002-11-27 | 2008-08-14 | Nycomed Gmbh | Neue synergistische zusammensetzung enthaltend roflumilast und formoterol |
| TW200426138A (en) * | 2002-12-10 | 2004-12-01 | Hoffmann La Roche | Novel arylene-carboxylic acid (2-amino-phenyl)-amide derivatives, their manufacture and use as pharmaceutical agents |
| WO2004067006A1 (en) * | 2003-01-27 | 2004-08-12 | Pharmacia Corporation | Combination of a pde iv inhibitor and a tnf-alpha antagonist |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| ES2335498T3 (es) * | 2003-03-10 | 2010-03-29 | Nycomed Gmbh | Nuevo proceso para la preparacion de reflumilast. |
| JP2006522151A (ja) | 2003-04-01 | 2006-09-28 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | 不妊症におけるホスホジエステラーゼ阻害剤 |
| WO2004089940A1 (en) | 2003-04-11 | 2004-10-21 | Glenmark Pharmaceuticals S.A. | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
| DE10318610A1 (de) * | 2003-04-24 | 2004-11-11 | Elbion Ag | 7-Azaindole und deren Verwendung als Therapeutika |
| WO2004098596A1 (en) * | 2003-05-12 | 2004-11-18 | Altana Pharma Ag | Composition comprising roflumilast and il-1 trap |
| WO2004098597A1 (en) * | 2003-05-12 | 2004-11-18 | Altana Pharma Ag | Composition comprising roflumilast and shuil-1r ii |
| WO2004098598A1 (en) * | 2003-05-12 | 2004-11-18 | Altana Pharma Ag | COMPOSITION COMPRISING ROFLUMILAST AND A TNFα ANTAGONIST |
| WO2004098595A1 (en) * | 2003-05-12 | 2004-11-18 | Altana Pharma Ag | COMPOSITION COMPRISING ROFLUMILAST AND A TNFα ANTAGONIST |
| EA012279B1 (ru) | 2003-05-22 | 2009-08-28 | Никомед Гмбх | Композиция, включающая ингибитор pde4 и ингибитор pde5 |
| MXPA05012900A (es) * | 2003-05-30 | 2006-02-22 | Ranbaxy Lab Ltd | Derivados de pirrol sustituidos. |
| US20090274676A1 (en) * | 2003-07-31 | 2009-11-05 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| US20050085430A1 (en) * | 2003-07-31 | 2005-04-21 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| US20050026883A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| JP2007504123A (ja) * | 2003-08-29 | 2007-03-01 | ランバクシー ラボラトリーズ リミテッド | Ｉｖ型ホスホジエステラーゼの阻害剤 |
| WO2005023253A1 (en) | 2003-09-05 | 2005-03-17 | Altana Pharma Ag | Use of pde4 inhibitors for the treatment of diabetes mellitus |
| EP1670742A1 (en) * | 2003-09-12 | 2006-06-21 | Ranbaxy Laboratories Limited | Process for the preparation of roflumilast |
| US20070117861A1 (en) * | 2003-11-12 | 2007-05-24 | University Of South Carolina | Treatment or prevention of cardiovascular and respiratory disorders with novel substituted cyclic-amp specific phosphodiesterase inhibitors |
| PT1685849E (pt) * | 2003-11-20 | 2012-02-15 | Astellas Pharma Inc | Inibidores de pde4 para o tratamento da cistite intersticial |
| WO2005051931A2 (en) * | 2003-11-26 | 2005-06-09 | Ranbaxy Laboratories Limited | Phosphodiesterase inhibitors |
| MY141255A (en) * | 2003-12-11 | 2010-03-31 | Memory Pharm Corp | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs |
| DK1713473T3 (da) * | 2004-02-06 | 2013-06-17 | Meda Pharma Gmbh & Co Kg | Kombination af anticholinergika og glucocorticoider til langtidsbehandling af astma og COPD |
| EP1713471B1 (en) * | 2004-02-06 | 2012-01-18 | MEDA Pharma GmbH & Co. KG | Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases |
| JP4728259B2 (ja) | 2004-02-18 | 2011-07-20 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 効果的なホスホジエステラーゼ（ｐｄｅ）４インヒビターとしての新規のグアニジニル置換されたヒドロキシ−６−フェニルフェナントリジン |
| EP1720543A1 (en) * | 2004-02-27 | 2006-11-15 | Altana Pharma AG | Roflumilast and glycopryrronium combination |
| MX341474B (es) | 2004-03-03 | 2016-08-19 | Takeda Gmbh | Nuevas hidroxi-6-heteroarilfenantridinas y su uso como inhibidores de la fosfodiesterasa tipo 4 ( pde4). |
| US20060035939A1 (en) * | 2004-07-14 | 2006-02-16 | Japan Tobacco Inc. | 3-Aminobenzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity |
| CA2571133C (en) * | 2004-07-15 | 2011-04-19 | Japan Tobacco Inc. | Fused benzamide compound and vanilloid receptor 1 (vr1) activity inhibitor |
| US20080009535A1 (en) * | 2004-08-30 | 2008-01-10 | Sarala Balachandran | Inhibitors of phosphodiesterase type-IV |
| DE102004046235A1 (de) | 2004-09-22 | 2006-03-30 | Altana Pharma Ag | Arzneimittelzubereitung |
| DE102004046236A1 (de) * | 2004-09-22 | 2006-03-30 | Altana Pharma Ag | Arzneimittelzubereitung |
| JPWO2006041121A1 (ja) * | 2004-10-13 | 2008-05-15 | 協和醗酵工業株式会社 | 慢性皮膚疾患の治療および／または予防剤 |
| WO2006040652A2 (en) | 2004-10-13 | 2006-04-20 | Glenmark Pharmaceuticals S.A. | Process for the preparation of n-(3,5-dichloropyrid-4-yl)-4difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-1-carboxamide |
| WO2006041120A1 (ja) * | 2004-10-13 | 2006-04-20 | Kyowa Hakko Kogyo Co., Ltd. | 医薬組成物 |
| PT1831227E (pt) | 2004-12-17 | 2013-08-23 | Glenmark Pharmaceuticals Sa | Proteínas buganina modificadas, citotoxinas e métodos e utilizações das mesmas |
| AP2334A (en) | 2004-12-17 | 2011-12-06 | Glenmark Pharmaceuticals Sa | Novel heterocyclic compounds useful for the treatment of inflamatory and allergic disorders. |
| WO2006094640A2 (en) * | 2005-03-04 | 2006-09-14 | F.Hoffmann-La Roche Ag | Roflumilast and integrin inhibitor combination and method of treatment |
| EA015382B1 (ru) | 2005-03-08 | 2011-08-30 | Никомед Гмбх | Применение рофлумиласта для лечения сахарного диабета типа 2 |
| WO2006094942A1 (en) * | 2005-03-08 | 2006-09-14 | Nycomed Gmbh | Roflumilast for the treatment of diabetes mellitus |
| AU2006224842B2 (en) * | 2005-03-16 | 2011-09-29 | Meda Pharma Gmbh & Co Kg | The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases |
| JP5383183B2 (ja) | 2005-03-16 | 2014-01-08 | タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング | ロフルミラストを含有する矯味された剤形 |
| PL2366393T3 (pl) | 2005-04-19 | 2014-01-31 | Takeda Gmbh | Roflumilast do leczenia nadciśnienia płucnego |
| US20080221111A1 (en) * | 2005-05-11 | 2008-09-11 | Nycomed Gmbh | Combination of a Pd4 Inhibitor and a Tetrahydrobiopterin Derivative |
| RU2007149249A (ru) * | 2005-06-09 | 2009-07-20 | Сантен Фармасьютикал Ко., Лтд (Jp) | Глазные капли, содержащие рофлумиласт |
| EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| EP1928437A2 (en) | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| AU2006304787A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
| CN101291664A (zh) * | 2005-10-24 | 2008-10-22 | 诺瓦提斯公司 | 组蛋白脱乙酰基酶抑制剂与放射的组合 |
| WO2007053596A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| KR101329112B1 (ko) * | 2005-11-08 | 2013-11-14 | 랜박시 래보러터리스 리미티드 | (3ｒ,5ｒ)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법 |
| DE602006008665D1 (de) * | 2005-12-21 | 2009-10-01 | Meda Pharma Gmbh & Co Kg | Kombination von r,r-glycopyrrolat, rolipram und budesonid zur behandlung von entzündungskrankheiten |
| US7906508B2 (en) * | 2005-12-28 | 2011-03-15 | Japan Tobacco Inc. | 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity |
| US7863446B2 (en) * | 2006-01-19 | 2011-01-04 | Orchid Research Laboratories Limited | Heterocycles |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP1991212A1 (en) * | 2006-03-08 | 2008-11-19 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| AR059838A1 (es) * | 2006-03-14 | 2008-04-30 | Ranbaxy Lab Ltd | Formulaciones para dosis estabilizantes de estatina |
| US20100009983A1 (en) * | 2006-05-09 | 2010-01-14 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| EP2382975A3 (en) | 2006-05-09 | 2012-02-29 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| MX2008014320A (es) * | 2006-05-09 | 2009-03-25 | Braincells Inc | Neurogenesis mediada por el receptor de 5-hidroxitriptamina. |
| PL2363130T3 (pl) | 2006-07-05 | 2014-09-30 | Astrazeneca Ab | Kombinacja inhibitorów reduktazy HMG-CoA atorwastatyny i symwastatyny z inhibitorem fosfodiesterazy, takim jak roflumilast do leczenia zapalnych chorób płuc |
| EP2049102A4 (en) * | 2006-07-14 | 2010-12-22 | Ranbaxy Lab Ltd | POLYMORPHIC FORMS OF AN HMG COA REDUCTASE HEATHER AND USE |
| US20100056791A1 (en) | 2006-09-01 | 2010-03-04 | Yasushi Kohno | Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same |
| EP2068872A1 (en) * | 2006-09-08 | 2009-06-17 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| CA2663347A1 (en) * | 2006-09-19 | 2008-03-27 | Braincells, Inc. | Ppar mediated modulation of neurogenesis |
| EP2066661A2 (en) * | 2006-09-22 | 2009-06-10 | Ranbaxy Laboratories Limited | Phosphodiesterase inhibitors |
| US20080221103A1 (en) * | 2007-03-09 | 2008-09-11 | Orchid Research Laboratories Ltd. | New heterocyclic compounds |
| KR100844125B1 (ko) * | 2007-03-23 | 2008-07-04 | 한국화학연구원 | 7-(3′,4′-디알콕시페닐)-[1,2,4]트리아졸로[1,5-ａ]피리미딘 화합물, 이의 제조방법 및 이를 포함하는 천식 및만성폐쇄성 폐질환을 포함한 염증관련 질환, 관절염,아토피 피부염, 암 및 뇌질환의 치료 및 예방을 위한약제학적 조성물 |
| HRP20110940T1 (hr) | 2007-05-16 | 2012-01-31 | Nycomed Gmbh | Derivati pirazolona kao inhibitori pde4 |
| ES2559319T3 (es) | 2007-06-04 | 2016-02-11 | Synergy Pharmaceuticals Inc. | Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| JP5240205B2 (ja) | 2008-01-11 | 2013-07-17 | アステラス製薬株式会社 | 精巣の疼痛又は不快感行動及び頻尿併発モデル動物 |
| US8420653B2 (en) | 2008-02-01 | 2013-04-16 | Orchid Chemicals & Pharmaceuticals Limited | Pyrimidine compounds and their uses |
| CA2726917C (en) | 2008-06-04 | 2018-06-26 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| WO2010003084A2 (en) * | 2008-07-02 | 2010-01-07 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors |
| WO2010009319A2 (en) | 2008-07-16 | 2010-01-21 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| EP2216327A1 (en) * | 2009-02-06 | 2010-08-11 | CHIESI FARMACEUTICI S.p.A. | Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| UY33372A (es) | 2010-05-10 | 2011-12-30 | Gilead Sciences Inc | ?análogos de quinolina bi?funcionales, su uso en la manufactura de medicamentos,composiciones que los comprenden y procesos de preparacion?. |
| UY33373A (es) | 2010-05-10 | 2011-12-30 | Gilead Sciences Inc | ?Compuestos de pirazolopiridina bifuncionales, su uso en terapia y composiciones que los comprenden?. |
| UA109140C2 (uk) * | 2010-06-24 | 2015-07-27 | Гетероциклічні сполуки бензодіоксолу або бензодіоксепіну як інгібітори фосфодіестераз | |
| CN102311382B (zh) * | 2010-06-29 | 2014-05-21 | 大道隆达（北京）医药科技发展有限公司 | 罗氟司特的晶态及其制备方法 |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| CN102093194B (zh) * | 2010-12-24 | 2014-01-08 | 江苏先声药物研究有限公司 | 3-环丙基甲氧基-4-二氟甲氧基苯甲酸的合成方法 |
| CN102617457A (zh) * | 2011-01-28 | 2012-08-01 | 天津药物研究院 | 一种制备罗氟司特的新方法 |
| DK2681236T3 (en) | 2011-03-01 | 2018-04-16 | Synergy Pharmaceuticals Inc | PROCEDURE FOR MANUFACTURING GUANYLATE CYCLASE-C-AGONISTS |
| CN102690194B (zh) * | 2011-03-24 | 2014-06-25 | 上海通远生物科技有限公司 | 3-环丙基甲氧基-4-二氟甲氧基苯甲酸的制备方法 |
| CN102775345A (zh) * | 2011-05-13 | 2012-11-14 | 上海特化医药科技有限公司 | 制备罗氟司特的方法及中间体 |
| CN102276522B (zh) * | 2011-06-15 | 2013-04-17 | 无锡泓兴生物医药科技有限公司 | 一种制备罗氟司特的方法及其中间体 |
| CN102336703B (zh) * | 2011-07-20 | 2013-09-25 | 华润赛科药业有限责任公司 | 一种制备罗氟司特的方法 |
| CN102351787B (zh) * | 2011-08-18 | 2014-08-13 | 天津市汉康医药生物技术有限公司 | 高生物利用度的罗氟司特化合物 |
| WO2013030789A1 (en) | 2011-08-30 | 2013-03-07 | Ranbaxy Laboratories Limited | Pharmaceutical oral solid dosage form containing a poorly water soluble pde - iv inhibitor |
| CN102336704B (zh) * | 2011-10-19 | 2013-04-17 | 丁克 | 一种制备罗氟司特的方法 |
| CA2852723A1 (en) * | 2011-10-21 | 2013-04-25 | Chiesi Farmaceutici S.P.A. | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors |
| CN102336705B (zh) * | 2011-10-28 | 2013-03-27 | 成都苑东药业有限公司 | 一种制备n-(3,5-二氯吡啶-4-基)-3-环丙基甲氧基-4-二氟甲氧基苯甲酰胺的方法 |
| WO2013072938A2 (en) | 2011-11-09 | 2013-05-23 | Mylan Laboratories Ltd | An improved process for the preparation of roflumilast |
| WO2013081565A1 (en) | 2011-11-21 | 2013-06-06 | Mahmut Bilgic | Pharmaceutical compositions comprising roflumilast and terbutaline |
| WO2013077830A1 (en) | 2011-11-25 | 2013-05-30 | Mahmut Bilgic | Synergistilly active combinations of roflumilast and carmoterol |
| WO2013084182A1 (en) | 2011-12-08 | 2013-06-13 | Glenmark Pharmaceuticals S.A. | Pharmaceutical composition that includes a pde4 enzyme inhibitor and an analgesic agent |
| CN102603623A (zh) * | 2011-12-26 | 2012-07-25 | 北京赛林泰医药技术有限公司 | 制备高纯度罗氟司特的方法 |
| EP2804603A1 (en) | 2012-01-10 | 2014-11-26 | President and Fellows of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| WO2013131255A1 (en) | 2012-03-07 | 2013-09-12 | Scinopharm (Changshu) Pharmaceutical, Ltd. | Preparation method of roflumilast |
| WO2014012954A1 (en) | 2012-07-18 | 2014-01-23 | Takeda Gmbh | Treatment of partly controlled or uncontrolled severe asthma |
| CN103630613B (zh) * | 2012-08-21 | 2015-08-05 | 北大方正集团有限公司 | 分离并检测罗氟司特及其中间体的方法 |
| WO2014060464A1 (en) | 2012-10-17 | 2014-04-24 | Interquim, S.A. | Process for preparing roflumilast |
| KR102154104B1 (ko) | 2013-01-28 | 2020-09-09 | 인코젠 쎄라퓨틱스 프라이빗 리미티드 | 로플루밀라스트 n- 옥사이드의 흡입에 의한 자가면역, 호흡 및 염증성 장애의 치료방법 |
| AU2014211755B2 (en) | 2013-02-04 | 2017-07-06 | Grunenthal Gmbh | 4-amino substituted condensed pyrimidine compounds as PDE4 inhibitors |
| EP2951173B1 (en) | 2013-02-04 | 2017-05-17 | Grünenthal GmbH | Novel substituted condensed pyrimidine compounds |
| JP6499591B2 (ja) | 2013-02-25 | 2019-04-10 | シナジー ファーマシューティカルズ インコーポレイテッド | 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト |
| CA2905438A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
| TW201512189A (zh) | 2013-04-16 | 2015-04-01 | Gruenenthal Chemie | 新型被取代之嘧啶縮合化合物 |
| WO2014197720A2 (en) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
| CN103304475A (zh) * | 2013-06-13 | 2013-09-18 | 湖南千金湘江药业股份有限公司 | 苯甲酰胺化合物及其制备方法和用途 |
| HUE035967T2 (hu) | 2013-08-09 | 2018-06-28 | Gruenenthal Gmbh | Új helyettesített kondenzált pirimidinvegyületek |
| CN105979959B (zh) | 2013-08-09 | 2021-11-30 | 阿德利克斯公司 | 用于抑制磷酸盐转运的化合物和方法 |
| US10357486B2 (en) | 2013-08-16 | 2019-07-23 | Universiteit Maastricht | Treatment of cognitive impairment with PDE4 inhibitor |
| WO2015063669A1 (en) | 2013-10-30 | 2015-05-07 | Wockhardt Limited | Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof |
| WO2015173701A2 (en) | 2014-05-12 | 2015-11-19 | Glaxosmithkline Intellectual Property (No. 2) Limited | Pharmaceutical compositions for treating infectious diseases |
| AR101197A1 (es) | 2014-07-16 | 2016-11-30 | Gruenenthal Gmbh | Pirimidinas 2,5-sustituidas |
| AR101198A1 (es) | 2014-07-16 | 2016-11-30 | Gruenenthal Gmbh | Pirimidinas 2,5-sustituidas como inhibidores de pde4b |
| AR101196A1 (es) | 2014-07-16 | 2016-11-30 | Gruenenthal Gmbh | Compuestos de pirimidina sustituidos |
| CN104130116B (zh) * | 2014-08-18 | 2015-11-11 | 朱丽平 | 一种制备罗氟司特中间体的方法 |
| CN106573889B (zh) | 2014-10-24 | 2019-01-01 | 久光制药株式会社 | 前药 |
| CN104447245B (zh) * | 2014-10-29 | 2017-06-06 | 成都森科制药有限公司 | 罗氟司特中间体、中间体制备方法及罗氟司特的制备方法 |
| KR20170034707A (ko) | 2015-09-21 | 2017-03-29 | 한미약품 주식회사 | 로플루밀라스트 함유 경구용 고형제제 및 그 제조방법 |
| EP3165224A1 (en) | 2015-11-09 | 2017-05-10 | Albert-Ludwigs-Universität Freiburg | Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders |
| WO2017089347A1 (en) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas |
| CN105523954B (zh) * | 2016-02-05 | 2017-07-18 | 徐江平 | 3‑环丙甲氧基‑4‑烷氧基苯甲酰胺类磷酸二酯酶4抑制剂 |
| US20210161870A1 (en) | 2017-06-07 | 2021-06-03 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
| US11129818B2 (en) | 2017-06-07 | 2021-09-28 | Arcutis Biotherapeutics, Inc. | Topical roflumilast formulation having improved delivery and plasma half life |
| US12042487B2 (en) | 2018-11-16 | 2024-07-23 | Arcutis Biotherapeutics, Inc. | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
| US12011437B1 (en) | 2017-06-07 | 2024-06-18 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
| US9895359B1 (en) | 2017-06-07 | 2018-02-20 | Arcutis, Inc. | Inhibition of crystal growth of roflumilast |
| US20200155524A1 (en) | 2018-11-16 | 2020-05-21 | Arcutis, Inc. | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
| US11534493B2 (en) | 2017-09-22 | 2022-12-27 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents |
| PT3700529T (pt) | 2017-10-23 | 2025-09-17 | Boehringer Ingelheim Int | Nova combinação de agentes ativos para o tratamento das doenças pulmonares intersticiais fibrosantes progressivas (dpi-fp |
| MX2020013192A (es) | 2018-06-04 | 2021-08-16 | Arcutis Inc | Metodo y formulacion para mejorar el tiempo de retraso de penetracion en la piel de roflumilast. |
| WO2020237096A1 (en) | 2019-05-21 | 2020-11-26 | Ardelyx, Inc. | Combination for lowering serum phosphate in a patient |
| JP2023513092A (ja) | 2020-01-31 | 2023-03-30 | アーキュティス・バイオセラピューティクス・インコーポレーテッド | 向上した送達および血漿半減期を有する局所用ロフルミラスト配合物 |
| WO2021213455A1 (zh) | 2020-04-23 | 2021-10-28 | 浙江养生堂天然药物研究所有限公司 | 药物组合及其用途 |
| CN111777550A (zh) * | 2020-06-01 | 2020-10-16 | 山东希尔康泰药业有限公司 | 罗氟司特结晶性粉末原料药生产制备方法 |
| MX2023006602A (es) | 2020-12-04 | 2023-08-07 | Arcutis Biotherapeutics Inc | Formulación tópica de roflumilast que tiene propiedades antimicoticas. |
| WO2022156727A1 (zh) | 2021-01-21 | 2022-07-28 | 浙江养生堂天然药物研究所有限公司 | 治疗肿瘤的组合物及方法 |
| WO2022169615A1 (en) | 2021-02-05 | 2022-08-11 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
| MX2023009352A (es) | 2021-02-10 | 2023-08-16 | Iolyx Therapeutics Inc | Metodos para la administracion oftalmica de roflumilast. |
| EP4405048A4 (en) | 2021-09-22 | 2025-08-06 | Iolyx Therapeutics Inc | METHODS OF TREATMENT OF INFLAMMATORY EYE DISEASES |
| EP4456870A1 (en) | 2021-12-28 | 2024-11-06 | Arcutis Biotherapeutics, Inc. | Topical roflumilast aerosol foams |
| JP2025501247A (ja) | 2021-12-28 | 2025-01-17 | アーキュティス・バイオセラピューティクス・インコーポレーテッド | 局所用エアゾールフォーム |
| JP2025530005A (ja) | 2022-09-15 | 2025-09-09 | アーキュティス・バイオセラピューティクス・インコーポレーテッド | ロフルミラスト及び大量のロフルミラストを溶解可能な溶媒の医薬組成物 |
| GB202306662D0 (en) | 2023-05-05 | 2023-06-21 | Union Therapeutics As | Dosage regimen |
| GB202306663D0 (en) | 2023-05-05 | 2023-06-21 | Union Therapeutics As | Combination therapy |
| US20250082618A1 (en) | 2023-09-07 | 2025-03-13 | Arcutis Biotherapeutics, Inc. | Dosing regimens using topical roflumilast compositions |
| US20250090509A1 (en) | 2023-09-15 | 2025-03-20 | Arcutis Biotherapeutics, Inc. | Methods of reducing itch using topical roflumilast compositions |
| WO2025265054A2 (en) | 2024-06-21 | 2025-12-26 | Arcutis Biotherapeutics, Inc. | Methods of treatment using topical roflumilast compositions |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3308239A1 (de) * | 1983-03-09 | 1984-09-13 | Basf Ag, 6700 Ludwigshafen | N-acyl-anthranilsaeurederivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses |
| DK159431C (da) * | 1984-05-10 | 1991-03-18 | Byk Gulden Lomberg Chem Fab | 6-phenyl-3(2h)-pyridazinoner, fremgangsmaade til fremstilling deraf, laegemidler indeholdende disse samt anvendelse af forbindelserne til fremstilling af laegemidler |
| JPS62158253A (ja) * | 1985-12-28 | 1987-07-14 | Kirin Brewery Co Ltd | ４−アミノピリジンアミド誘導体 |
| SU1512053A1 (ru) * | 1988-01-29 | 1991-01-15 | Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского | 2-Окси-3,5-дигалоид-N-[3-хлор-4-(4-галоиднафтокси-1)-фенил]-бензамиды, обладающие активностью при экспериментальном описторхозе и гименолепидозе |
| IE71647B1 (en) * | 1991-01-28 | 1997-02-26 | Rhone Poulenc Rorer Ltd | Benzamide derivatives |
| EP0581805A1 (de) * | 1991-04-26 | 1994-02-09 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Neue pyridazine |
| DE69309030T2 (de) * | 1992-06-15 | 1997-09-25 | Celltech Therapeutics Ltd | Trisubstituierte phenylderivate als selektive phosphodiesterase iv inhibitoren |
| GB9212693D0 (en) * | 1992-06-15 | 1992-07-29 | Celltech Ltd | Chemical compounds |
| AU4717693A (en) * | 1992-07-28 | 1994-02-14 | Rhone-Poulenc Rorer Limited | Inhibitors of c-amp phosphodiesterase and tnf |
-
1994
- 1994-07-02 SK SK1617-95A patent/SK283263B6/sk not_active IP Right Cessation
- 1994-07-02 SI SI9430420T patent/SI0706513T1/xx unknown
- 1994-07-02 US US08/564,322 patent/US5712298A/en not_active Expired - Lifetime
- 1994-07-02 RU RU96102569A patent/RU2137754C1/ru active Protection Beyond IP Right Term
- 1994-07-02 DE DE122010000043C patent/DE122010000043I1/de active Pending
- 1994-07-02 NZ NZ271316A patent/NZ271316A/en not_active IP Right Cessation
- 1994-07-02 AT AT94924713T patent/ATE217612T1/de active
- 1994-07-02 WO PCT/EP1994/002169 patent/WO1995001338A1/de not_active Ceased
- 1994-07-02 CN CN94192659A patent/CN1046939C/zh not_active Expired - Lifetime
- 1994-07-02 DE DE59410119T patent/DE59410119D1/de not_active Expired - Lifetime
- 1994-07-02 HU HU9503541A patent/HU220041B/hu active Protection Beyond IP Right Term
- 1994-07-02 KR KR1019950705937A patent/KR100331255B1/ko not_active Expired - Lifetime
- 1994-07-02 JP JP07503287A patent/JP3093271B2/ja not_active Expired - Lifetime
- 1994-07-02 CA CA002165192A patent/CA2165192C/en not_active Expired - Lifetime
- 1994-07-02 CZ CZ19961A patent/CZ290266B6/cs not_active IP Right Cessation
- 1994-07-02 AU AU74907/94A patent/AU687087B2/en not_active Expired
- 1994-07-02 PT PT94924713T patent/PT706513E/pt unknown
- 1994-07-02 SG SG9605206-3A patent/SG143011A1/en unknown
- 1994-07-02 ES ES94924713T patent/ES2176252T3/es not_active Expired - Lifetime
- 1994-07-02 PL PL94311820A patent/PL178314B1/pl unknown
- 1994-07-02 DK DK94924713T patent/DK0706513T3/da active
- 1994-07-02 EP EP94924713A patent/EP0706513B1/de not_active Expired - Lifetime
-
1995
- 1995-12-21 NO NO19955211A patent/NO305598B1/no not_active IP Right Cessation
- 1995-12-29 FI FI956333A patent/FI112864B/fi not_active IP Right Cessation
-
2003
- 2003-05-13 LV LVP-03-48A patent/LV13074B/lv unknown
- 2003-11-11 CY CY0300082A patent/CY2389B1/xx unknown
-
2010
- 2010-07-21 LU LU91709C patent/LU91709I2/fr unknown
- 2010-09-29 CY CY2010015C patent/CY2010015I1/el unknown
- 2010-09-30 NO NO2010018C patent/NO2010018I1/no unknown
- 2010-12-06 FR FR10C0052C patent/FR10C0052I2/fr active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LV13074B (en) | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors | |
| EP0772610B9 (de) | Dihydrobenzofurane | |
| DE60313472T2 (de) | Pyrrolidindion-substituierte piperidin-phthalazone als pde4-inhibitoren | |
| DE69809754T2 (de) | Substituierte 6-phenylphenanthridine | |
| EP0828728B1 (de) | Phenyldihydrobenzofurane | |
| DE69822162T2 (de) | Neue tetrazolderivate | |
| EP1086096B1 (de) | Benzamide mit tetrahydrofuranyloxy-substituenten als inhibitoren der phosphodiesterase 4 | |
| EP0920426B1 (de) | Neue thiazol-derivate mit phosphodiesterase inhibierender wirkung | |
| WO2002042301A1 (de) | Neue pyridin-substituierte pyrazolopyridinderivate | |
| EP1109810B1 (de) | Benzonaphthyridin-n-oxide mit pde3 und pde4 inhibierender aktivität | |
| DE69817548T2 (de) | Tetrazole derivate | |
| DE69808099T2 (de) | Substituierte 6-alkylphenanthridine | |
| WO1998008830A1 (de) | Thiazol-derivate als selektive inhibitoren der pde-iv | |
| WO1998021207A1 (de) | (2,3-dihydrobenzofuranyl)-thiazole als phosphodiesterasehemmer | |
| DE60020079T2 (de) | Phenanthridin-N-oxide mit PDE-IV-hemmender Wirkung | |
| DE60202669T2 (de) | 6-phenylbenzonaphthyidine | |
| EP0557879A1 (de) | 4-Amino-2-ureido-pyrimidin-5-carbonsäureamide, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung | |
| EP0819688A1 (de) | 4-substituierte Benzofurane | |
| DE3419223C2 (de) | Substituierte Acylpiperazinochinazoline, ein Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zubereitungen | |
| DE2143730A1 (de) | Substituierte pyridine, verfahren zu deren herstellung und sie enthaltende arzneimittel | |
| DE2210687B2 (de) | 2,6-Diamino-33-diäthoxycarbonyldihydropyridine, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel | |
| DE69714019T2 (de) | 1,4-dihydropyridin-verbindungen als bradykinin-antagonisten | |
| DE1620121A1 (de) | Verfahren zur Herstellung von Pyridin- und Diazinverbindungen | |
| US3312712A (en) | 2-(3-carboxyl and 3-carbamyl-pyridinium) succinic acid betaines and a method for their preparation | |
| DE60313331T2 (de) | Neue benzonaphthyridine |